Dual Treatment With Lithium and Valproate in ALS.

Inclusion Criteria: * patients aged 40 to 70 years * of both genders * female patients who are either postmenopausal for at least 24 months or who are able to practice 2 methods of contraception. * Clinical diagnosis of definite ALS supported by neurophysiological studies, according to El Escorial reviewed criteria and Awaji criteria. * Sporadic ALS, a priori. * Onset of weakness for 1 year ± 6 months * Vital capacity of at least 60 % of the predicted value * Other treatment (with riluzole or not) at fixed dosis 2 months before and during all the clinical trial. * Patients who are willing to give informed consent * Without gastrostomy * Without jejunostomy * Without traqueostomy Exclusion Criteria: * Age less than 25 years\*\* * Patients with uncontrolled diabetes * Patient with heart failure * Patient with respiratory vital capacity \< 60% * Hepatic failure * Dysthyroidism * Do not give or sign informed consent * Women in lactation, pregnancy or possibility of pregnancy * Patients with significant sensory abnormalities and uncompensated medical illnesses * Laboratory abnormalities consistent with clinically significant cardiovascular, respiratory, haematological, metabolic, hepatic and renal disease. * Patients with gastrostomy * With jejunostomy * With nasogastric tube * Tracheotomy and invasive ventilation * Treatment with investigational drug within 3 months prior to screening * Patients aged 26 to 39 years can be included at the discretion of medical researchers.